James Moore: Astra’s new drugs could rekindle Pfizer’s interest
Your support helps us to tell the story
As your White House correspondent, I ask the tough questions and seek the answers that matter.
Your support enables me to be in the room, pressing for transparency and accountability. Without your contributions, we wouldn't have the resources to challenge those in power.
Your donation makes it possible for us to keep doing this important work, keeping you informed every step of the way to the November election
Andrew Feinberg
White House Correspondent
Outlook The single life seems to be suiting AstraZeneca. Touting an “industry-leading” line-up of hot new cancer drugs, the company has secured the endorsement of super-fund manager Neil Woodford, who gushed that his belief in the company’s independent future was “even stronger”.
The company’s research base is producing just the sort of results that people feared would be threatened by Pfizer’s predatory intentions. Worryingly, however, they may rekindle its interest. The Obama administration might have squeezed some of the taxation advantages a takeover would have provided, but Astra’s pipeline could make up for that.
Pfizer’s previous approach sparked an intense national debate. Astra’s success with cancer, however, should make that global if Pfizer comes back.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments